Naphazoline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Naphazoline: From Ophthalmic Decongestant to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Naphazoline is an imidazoline alpha-adrenergic agonist and vasoconstrictor, used as an ophthalmic decongestant. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp with a very high score. However, there are 0 clinical trials and 0 relevant publications for this prediction, so it rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ophthalmic vasoconstrictor/decongestant (based on drug class; the registration records do not state an indication) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Naphazoline is known as an imidazoline alpha-adrenergic agonist. It narrows blood vessels, which is how it relieves redness and congestion in the eye.
The link between this action and hair loss is weak. A vasoconstrictor would, if anything, reduce blood flow to the scalp, which is the opposite of established hair-growth agents. The high score most likely reflects proximity to hair-related nodes in the knowledge graph rather than a real pharmacological relationship. It should be treated as a probable model artifact.
The top 10 predictions show the same pattern. Most are hair disorders or rare congenital conditions with no mechanistic link to naphazoline:
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 1 | Hypotrichosis simplex of the scalp | 99.83% | L5 | No plausible pathway |
| 2 | Congenital hypotrichosis milia | 99.82% | L5 | Rare genetic disorder |
| 3 | Diffuse alopecia areata | 99.79% | L5 | Autoimmune; no immunomodulatory action |
| 4 | Alopecia | 99.76% | L5 | Vasoconstriction runs opposite to hair-growth agents |
| 5 | Primary hereditary glaucoma | 99.62% | L5 | Class analogy to alpha-2 agonists only; safety concern |
| 6 | Hypertrichosis | 99.60% | L5 | Opposite phenotype to ranks 1-4, which suggests a non-specific score |
| 7 | Ambras type hypertrichosis universalis congenita | 99.60% | L5 | Rare genetic disorder |
| 8 | Open-angle glaucoma | 99.59% | L5 | The one retrieved paper does not involve naphazoline |
| 9 | Malformation syndrome with odontal/periodontal component | 99.57% | L5 | Retrieved literature matches disease terms only |
| 10 | Syndrome with Dandy-Walker malformation | 99.52% | L5 | Congenital brain malformation |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top prediction.
Two lower-ranked predictions returned papers, but none concern naphazoline:
- Open-angle glaucoma: one 1992 paper (PMID 1295525) on topical corticosteroids after laser trabeculoplasty.
- Periodontal malformation syndrome: generic periodontitis guidelines and reviews, which appear to match on disease terms only.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. H 1272 (Act 101/1965) | Oculosan 10ml | Drops |
| Reg. No. H1236 (OM) | Covomycin 7.5ml | Een (as recorded) |
The records do not include approved indication text or Essential Medicines List (EML) status.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
One caution comes from the evidence review. Ophthalmic vasoconstrictors carry an intraocular-pressure warning, and naphazoline labelling advises against use in narrow-angle glaucoma. This must be resolved before any glaucoma-related use is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: All predictions are model-only (L5) with no supporting trials or relevant literature. The pharmacology of a vasoconstrictor does not plausibly support hair growth, and the glaucoma predictions conflict with known safety cautions.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications), which is currently missing and blocks safety screening
- Mechanism of action data (for example from DrugBank)
- A plausible biological pathway, or preclinical evidence, linking naphazoline to hair follicle biology
- Route compatibility assessment: the registered products are ophthalmic drops, and no scalp formulation is registered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.